Results 361 to 370 of about 6,774,149 (386)
Some of the next articles are maybe not open access.
Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase
Nature, 2005H. Bryant +9 more
semanticscholar +1 more source
Specificity and mechanism of action of some commonly used protein kinase inhibitors.
Biochemical Journal, 2000S. Davies +3 more
semanticscholar +1 more source
2012
In May 2003, the US Food and Drug Administration (FDA) granted accelerated approval for the use of the first-in-class proteasome inhibitor bortezomib as a third-line therapy in multiple myeloma, and the European Union followed suit a year later. Bortezomib has subsequently been approved for multiple myeloma as a second-line treatment on its own and as ...
openaire +2 more sources
In May 2003, the US Food and Drug Administration (FDA) granted accelerated approval for the use of the first-in-class proteasome inhibitor bortezomib as a third-line therapy in multiple myeloma, and the European Union followed suit a year later. Bortezomib has subsequently been approved for multiple myeloma as a second-line treatment on its own and as ...
openaire +2 more sources
Understanding and overcoming resistance to PARP inhibitors in cancer therapy
Nature Reviews Clinical Oncology, 2021M. Dias +3 more
semanticscholar +1 more source
Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors
Nature Reviews Clinical Oncology, 2020L. Galluzzi +4 more
semanticscholar +1 more source
Matrix metalloproteinases and their inhibitors in connective tissue remodeling
The FASEB Journal, 1991J. Woessner
semanticscholar +1 more source
Anticancer activities of histone deacetylase inhibitors
Nature reviews. Drug discovery, 2006Jessica E. Bolden +2 more
semanticscholar +1 more source